Companies in Dermatology
There are 1,253 companies in Dermatology which include Revance Therapeutics, LEO Pharma, Castle Biosciences, DermTech, Evolus. 578 companies in Dermatology are funded, with 336 having secured Series A funding. Till date, the sector has seen the creation of 1 Unicorn. United States has the most number of companies in Dermatology (477), followed by United Kingdom
(96), and then South Korea (90).
2026 has seen the creation of 1 company in Dermatology. On average, the last 10 years have seen 33 new companies launched every year. Most number of Dermatology startups have been founded by alumni from Massachusetts Institute of Technology, Harvard University and Tel Aviv University.
Here is a List of top companies in Dermatology
Developer of neurotoxin aesthetic and therapeutic products for skin treatments. It focused on developing innovative products in the aesthetic medicine and personal wellness categories. It has developed a platform technology that enables the delivery of large macromolecules and other potent molecules across the skin. Its aesthetics pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines. It has the same products as therapies for Hyperhidrosis and Cervical Dystonia.
Key facts about Revance Therapeutics
- Founded Year: 2002
- Location: Newark (United States)
- Stage: Acquired
- Total Funding till date: $155M
- Investors: EW Healthcare Partners, Delphi Ventures and 16 Others
- Latest Funding Round: Series E, Oct 22, 2013, $*****
- Tracxn Score: 72/100 What is this?
- Competitors Rank: 1 of 228 Competitors
2. LEO Pharma
Developer of drugs for treating dermatology diseases. It offers variety of medicines such as topical creams and ointments, oral tablets, and injectable biologics for the treatment of psoriasis, eczema, and rare diseases. The pipeline products include Tralokinumab for atopic dermatitis and Delgocitinib a topical pan-JAK inhibitor for chronic hand eczema.
Key facts about LEO Pharma
- Founded Year: 1908
- Location: Copenhagen (Denmark)
- Stage: Late Stage
- Total Funding till date: $560M
- Investors: Nordic Capital
- Latest Funding Round: PE, Mar 31, 2022, $*****
- Tracxn Score: 71/100 What is this?
- Competitors Rank: 8 of 3,097 Competitors
Provider of diagnostic devices for treating cancer. The company's product includes prognostic tests used for uveal melanoma, esophageal cancer, mesothelioma, cutaneous melanoma, and glioblastoma multiforme. The company has also developed DecisionDx DiffDx-Melanoma to diagnose Melanocytic Lesions and others.
Key facts about Castle Biosciences
- Founded Year: 2008
- Location: Friendswood (United States)
- Stage: Public
- Total Funding till date: $62M
- Investors: Industry Ventures, Health Quest Capital and 9 Others
- Latest Funding Round: Post IPO, Jul 29, 2019, $*****
- Tracxn Score: 70/100 What is this?
- Competitors Rank: 6 of 542 Competitors
4. DermTech
DermTech develops qPCR assays and diagnostic aides for skin samples collected non-invasively to detect melanoma and skin cancer. It has a proprietary technology that allows skin 'biopsies' to be taken by applying an adhesive patch on the patient's skin. This patch can able to take cells present in the outermost skin layer and then analyze them for gene expression levels.
Key facts about DermTech
- Founded Year: 1996
- Location: San Diego (United States)
- Stage: Acquired
- Total Funding till date: $24.4M
- Investors: RTW Investments, Van Herk Groep and 3 Others
- Latest Funding Round: Post IPO, Mar 13, 2020, $*****
- Tracxn Score: 68/100 What is this?
- Competitors Rank: 3 of 175 Competitors
5. Evolus
Developer of aesthetic treatments and procedures. The company is focused on the development of self-pay aesthetic products. Its lead product candidate, DWP-450, is an injectable purified botulinum toxin type A complex. This molecule is in Phase II clinical trial for the treatment of moderate-to-severe glabellar lines.
Key facts about Evolus
- Founded Year: 2012
- Location: Irvine (United States)
- Stage: Public
- Total Funding till date: $500K
- Investors: Daewoong Pharmaceutical and De novo ventures
- Latest Funding Round: Post IPO, Apr 25, 2022, $*****
- Tracxn Score: 68/100 What is this?
- Competitors Rank: 2 of 228 Competitors
